EyePoint set for record drop after experimental eye drug misses late-stage study goal

EyePoint

17/08/2026 15:14

Updates
** Shares of EyePoint EYPT.O tumble 71% to $4.17, on track for their biggest one-day drop on record and lowest level since April 2025
** The drug developer says experimental eye drug Duravyu missed the main goal of a late-stage trial against Regeneron's blockbuster eye drug Eylea in patients with wet age-related macular degeneration, a leading cause of vision loss
** Adds that an analysis excluding nine patients whose vision loss was unrelated to wet AMD showed Duravyu performed similarly to Eylea
** Duravyu reduced treatment burden by 42% versus Eylea, or about two fewer injections through Week 56 - EYPT
** Says 54% patients were supplement-free through Week 56, 79% received zero or one supplemental injection
** Sees data from a second late-stage wet AMD study in Q4 2026, plans potential FDA filing in H1 2027
** Including session's move, stock down ~77% YTD

 (Reporting by Sahil Pandey in Bengaluru)
 ((Sahil.Pandey@thomsonreuters.com))